Kura Oncology Inc. (NASDAQ:KURA) rose 3.8% during trading on Friday . The company traded as high as $4.16 and last traded at $4.11, with a volume of 63,446 shares traded. The stock had previously closed at $3.96.

KURA has been the topic of a number of recent research reports. Oppenheimer Holdings Inc. reiterated an “outperform” rating and issued a $16.00 price objective on shares of Kura Oncology in a research report on Tuesday, June 21st. Zacks Investment Research upgraded Kura Oncology from a “hold” rating to a “buy” rating and set a $3.75 price objective on the stock in a research report on Wednesday, July 13th.

The company’s 50-day moving average price is $3.38 and its 200 day moving average price is $3.74. The stock’s market cap is $75.75 million.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Wednesday, May 11th. The company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by $0.01. Equities research analysts predict that Kura Oncology Inc. will post ($1.70) earnings per share for the current fiscal year.

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.